Urica Therapeutics

Urica Therapeutics, founded as a subsidiary of Fortress Biotech, is a clinical-stage biopharmaceutical company dedicated to developing and commercializing pharmaceutical products aimed at treating gout and chronic kidney diseases. The company's core mission is to innovate and provide effective treatments for these conditions, improving patient outcomes and quality of life. Urica's primary product in development is Dotinurad, a novel therapeutic for gout, which is currently undergoing clinical trials.

Notable figures associated with Urica Therapeutics include key members of its management team, board of directors, and scientific advisory board, who bring extensive experience in biopharmaceutical development. The company has achieved significant milestones in advancing Dotinurad through various stages of clinical trials, reflecting its commitment to addressing unmet medical needs. Urica's impact lies in its potential to offer new, effective treatments for patients suffering from gout and chronic kidney diseases, contributing to the broader field of biopharmaceutical innovation.